Evidence map›Paper›PMID 31086355›Full record

ReviewPediatric research2020

Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges.

Christopher R Nitkin, Johnson Rajasingh, Courtney Pisano, Gail E Besner, Bernard Thébaud, Venkatesh Sampath

Open access · hybridAbstract readReview
In one paragraph

Review in Pediatric research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Christopher R NitkinDivision of Neonatology, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA.
Johnson RajasinghDepartment of Cardiovascular Medicine, Cardiovascular Research Institute, University of Kansas Medical Center, Kansas City, MO, USA.
Courtney PisanoDepartment of Pediatric Surgery, Center for Perinatal Research, Nationwide Children's Hospital, Columbus, OH, USA.
Gail E BesnerDepartment of Pediatric Surgery, Center for Perinatal Research, Nationwide Children's Hospital, Columbus, OH, USA.
Bernard ThébaudDivision of Neonatology, Department of Pediatrics, Children's Hospital of Eastern Ontario (CHEO) and CHEO Research Institute, Ottawa, ON, Canada.
Venkatesh SampathDivision of Neonatology, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, MO, USA. vsampath@cmh.edu.
Children's Mercy Hospital · USNationwide Children's Hospital · USOttawa Hospital · CAUniversity of Kansas Medical Center · US

Funding

Single Immunoglobulin Interleukin-1 Related Receptor and necrotizing enterocolitis in premature infantsR01DK117296 · NIDDK · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI SAMPATH, VENKATESH, UMAR, SHAHID · 2018 to 2022
$2.6M
Inflammatory Angiogenesis in the LungR01HL128374 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI SAMPATH, VENKATESH · 2015 to 2020
$1.8M
scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy PatientsR01HL141345 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, RAJASINGH · 2019 to 2022
$1.5M
Exosomes and HB-EGF in Stem Cell-Mediated Therapy for Necrotizing EnterocolitisR01GM113236 · NIGMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BESNER, GAIL E · 2015 to 2018
$1.4M
CIHRNHLBI NIH HHS R01 HL128374NHLBI NIH HHS R01 HL141345NIDDK NIH HHS R01 DK117296NIGMS NIH HHS R01 GM113236
6 · The paper itself

Abstract

Diseases of the preterm newborn such as bronchopulmonary dysplasia, necrotizing enterocolitis, cerebral palsy, and hypoxic-ischemic encephalopathy continue to be major causes of infant mortality and long-term morbidity. Effective therapies for the prevention or treatment for these conditions are still lacking as recent clinical trials have shown modest or no benefit. Stem cell therapy is rapidly emerging as a novel therapeutic tool for several neonatal diseases with encouraging pre-clinical results that hold promise for clinical translation. However, there are a number of unanswered questions and facets to the development of stem cell therapy as a clinical intervention. There is much work to be done to fully elucidate the mechanisms by which stem cell therapy is effective (e.g., anti-inflammatory versus pro-angiogenic), identifying important paracrine mediators, and determining the timing and type of therapy (e.g., cellular versus secretomes), as well as patient characteristics that are ideal. Importantly, the interaction between stem cell therapy and current, standard-of-care interventions is nearly completely unknown. In this review, we will focus predominantly on the use of mesenchymal stromal cells for neonatal diseases, highlighting the promises and challenges in clinical translation towards preventing neonatal diseases in the 21st century.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsDiffusion of InnovationGestational AgeHumansInfant, NewbornInfant, Newborn, DiseasesInfant, PrematureTreatment Outcome

Identifiers

PMID31086355
PMCPMC6854309
OpenAlexW2945446123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.